IDH1 Mutation Increases the Sensitivity of Glioma Organoids to Radiotherapy and Targeted Therapy - PubMed
5 hours ago
- #IDH1 mutation
- #glioma organoids
- #precision medicine
- IDH1 mutation in gliomas is a key molecular marker distinguishing subtypes, with IDH1-mutant gliomas growing more slowly and being more sensitive to radiotherapy and chemotherapy.
- Organoid models simulate IDH1-mutant tumor characteristics, aiding personalized treatment research.
- Constructed glioma organoids showed consistency with original tumor tissues in immunohistochemical and immunofluorescence assays.
- IDH1-mutant organoids exhibited significantly higher sensitivity to vorasidenib compared to wild-type organoids, but no significant difference in temozolomide sensitivity.
- After γ-ray irradiation, IDH1-mutant glioma organoids showed a significant decrease in cell viability, unlike wild-type organoids.
- The study highlights the potential of IDH1-mutant glioma organoids as a platform for precision drug testing and advancing personalized glioma treatment.